Moleculin Biotech ( (MBRX) ) has shared an update.
On April 1, 2025, Moleculin Biotech announced the commencement of dosing for the first patient in its Phase 3 MIRACLE trial, which evaluates Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia (R/R AML). This trial marks a significant milestone for the company and the AML community, with initial data expected in the second half of 2025. The trial’s adaptive design and global scope aim to accelerate Annamycin’s development towards approval, potentially impacting Moleculin’s market positioning and providing valuable insights for stakeholders.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is designed to overcome multidrug resistance and reduce cardiotoxicity, targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
YTD Price Performance: -45.03%
Average Trading Volume: 5,791,155
Technical Sentiment Signal: Buy
Current Market Cap: $14.56M
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.